Sarepta Therapeutics Sees Unusually Large Options Volume (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) saw unusually large options trading activity on Tuesday. Traders purchased 3,559 call options on the company. This represents an increase of 71% compared to the typical daily volume of 2,081 call options.

Insider Transactions at Sarepta Therapeutics

In related news, insider Dallan Murray sold 3,635 shares of the business's stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares of the company's stock, valued at approximately $2,537,500. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Dallan Murray sold 3,635 shares of the company's stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stephen Mayo sold 3,135 shares of the company's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total transaction of $385,479.60. Following the transaction, the director now owns 6,621 shares of the company's stock, valued at approximately $814,118.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,731 shares of company stock worth $3,248,319. 7.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently made changes to their positions in the business. New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics in the 1st quarter worth about $32,000. Comerica Bank raised its position in Sarepta Therapeutics by 489.4% during the first quarter. Comerica Bank now owns 3,336 shares of the biotechnology company's stock valued at $432,000 after acquiring an additional 2,770 shares in the last quarter. Castleark Management LLC acquired a new stake in Sarepta Therapeutics in the first quarter valued at approximately $304,000. Tidal Investments LLC grew its position in Sarepta Therapeutics by 8.5% in the first quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company's stock worth $376,000 after acquiring an additional 228 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Sarepta Therapeutics by 26.3% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company's stock worth $75,040,000 after purchasing an additional 120,535 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Trading Down 1.3 %

Shares of Sarepta Therapeutics stock traded down $1.71 on Tuesday, reaching $129.12. 748,380 shares of the company were exchanged, compared to its average volume of 1,019,974. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $152.21. The firm has a market capitalization of $12.20 billion, a price-to-earnings ratio of 1,173.82 and a beta of 0.95. The stock has a fifty day moving average price of $126.83 and a 200-day moving average price of $113.60.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business's quarterly revenue was up 63.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.44) earnings per share. On average, analysts expect that Sarepta Therapeutics will post 2.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SRPT shares. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, May 2nd. Oppenheimer raised shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $180.00 price objective for the company in a report on Tuesday, May 14th. Citigroup increased their target price on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a "buy" rating in a research report on Thursday, February 29th. Evercore ISI boosted their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an "in-line" rating in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an "overweight" rating for the company in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $163.94.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.